Focus on Nintedanib in NSCLC and Other Tumors

Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and fibroblast growth factor receptors. Evidence about its efficacy in addition to second-line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzo, Anna, Carillio, Guido, Montanino, Agnese, Costanzo, Raffaele, Sandomenico, Claudia, Rocco, Gaetano, Morabito, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165233/
https://www.ncbi.nlm.nih.gov/pubmed/28066768
http://dx.doi.org/10.3389/fmed.2016.00068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165233/
https://www.ncbi.nlm.nih.gov/pubmed/28066768
http://dx.doi.org/10.3389/fmed.2016.00068

Ejemplares similares